Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

By R. Rouzier, Charles M. Perou, W. Symmans, N. Ibrahim, M. Cristofanilli, K. Anderson, K. Hess, J. Stec, M. Ayers, P. Wagner and 6 more. Clinical Cancer Research, 2005

1,940 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/462138b4a36c84ccba858826bf96d60dd51f40f1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Pathology and Forensic Medicine

Citations in the corpus

Triple negative tumours: a critical review (2007, background): “In those, and in subsequent studies, it has been shown that the basal-like group is enriched for tumours that lack expression of hormone receptors and of HER2 and has a more aggressive clinical behaviour,(5,8,10,11) a distinctive metastatic pattern(12,13) and a poor prognosis despite responding to c”
An overview of triple-negative breast cancer (2016, background): “As discussed, anthracycline and taxane-based regimens constitute today’s standard regimen for breast cancer (including TNBC) patients [113, 114].”
Triple-negative breast cancer--current status and future directions. (2009, methodology): “Most importantly, while the predictive impact of conventional ER, PgR and HER-2 measurements in the clinical setting is relatively clear, the clinical significance of molecular class remains to be determined.”
Triple-negative breast cancer: disease entity or title of convenience? (2010, background): “Despite historically poor outcomes in TNBC and/or BLBC, chemotherapy is effective, and improvements in chemotherapy are likely to preferentially benefit this subtype of breast cancer because of rapid proliferation rates and defects in DNA repair”
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes (2007, background): “A recent report revealed significantly higher pathologic complete response to neoadjuvant chemotherapy among basal-like and HER2+/ER subtypes compared with luminal subtypes (5).”
Basal-like breast cancer: a critical review. (2008, background): “adjuvant chemotherapy, whereas none of the normal breast–like cancers did so.(64) Furthermore, ER expression, as defined by immuno-”
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors (2007, background): “These studies emphasize that human breast cancers are multiple distinct diseases, with each of the major subtypes likely harboring different genetic alterations and responding distinctly to therapy [4,5].”
Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients (2007, background): “With the knowledge that basal-type and c-erb-B2-positive subtypes of breast cancer may respond better to certain chemotherapy regimens (as observed in the preoperative setting), the higher propensity for the former subtype in African–American women with breast cancer should result in the prompt init”
The humoral immune system has a key prognostic impact in node-negative breast cancer. (2008, neutral): “Mean 60 (SD, 12) 54 (SD, 12) 49 (SD, 9) V40 10 (5) 36 (13) 53 (18) 41–55 64 (32) 129 (45) 175 (58)”
Subtypes of breast cancer show preferential site of relapse. (2008, background): “Later studies reported differences in prognosis (2, 3) and chemotherapy response ( 4 ) with respect to the subtypes in specific patient cohorts.”